Repros Therapeutics (NASDAQ: RPRX) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Repros Therapeutics to similar businesses based on the strength of its earnings, risk, dividends, institutional ownership, valuation, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Repros Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repros Therapeutics 0 1 1 0 2.50
Repros Therapeutics Competitors 785 2925 6381 144 2.57

Repros Therapeutics currently has a consensus price target of $1.50, suggesting a potential upside of 371.70%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.35%. Given Repros Therapeutics’ higher possible upside, research analysts clearly believe Repros Therapeutics is more favorable than its rivals.

Volatility & Risk

Repros Therapeutics has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Repros Therapeutics’ rivals have a beta of 1.67, indicating that their average stock price is 67% more volatile than the S&P 500.

Profitability

This table compares Repros Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repros Therapeutics -56,062.07% -412.64% -212.24%
Repros Therapeutics Competitors -3,680.63% -414.16% -48.07%

Valuation & Earnings

This table compares Repros Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Repros Therapeutics N/A -$15.95 million -0.50
Repros Therapeutics Competitors $207.14 million -$2.51 million 0.26

Repros Therapeutics’ rivals have higher revenue and earnings than Repros Therapeutics. Repros Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

14.5% of Repros Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 2.5% of Repros Therapeutics shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Repros Therapeutics rivals beat Repros Therapeutics on 10 of the 12 factors compared.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.